Few consultants (17) agreed that the treatment of neurotic patients was "the job of any doctor." Altogether the clinicians were dissatisfied with the existing psychiatric services. These research methods may be criticised but the results confirm popular prejudices about psychiatry and psychiatrists.
Against this background, what are the prospects for psychiatry in the setting of a general hospital ? Most of the psychiatric disorders that present in hospital departments probably require no more special skill than could be provided by a physician and a social worker. Indeed, much of current thinking on the psychosocial assessment of patients who have attempted suicide,8 the most common psychiatric condition in hospitals, is in keeping with that view. Subtler sorts of psychiatric distress, however, come less easily to attention in the medical setting. If general physicians are to undertake more responsibility for the psychiatric care of their patients they will have to develop a greater sensitivity to abnormal mental states in the context of physical illness. Meanwhile psychiatry and psychiatrists are set to stay in the medical doldrums. "Liaison" psychiatry9-the subspecialty that provides psychiatric assessments on patients with physical disorders-lacks a coherent theoretical foundation. The conclusion, clearly, is that in the future all hospital doctors should understand and apply the principles and practice of psychological medicine.
I Shepherd M, Davies Tardive dyskinesia includes orolingual dyskinesia, chorea, athetosis, dystonia, and tics, but not rhythmic tremor. It ranges in severity from isolated dyskinesias to widespread, disabling dystonias which interfere with walking and feeding. Separate but related syndromes may exist within the general condition.2 Dyskinesias appear after months or years of treatment with antipsychotic drugs and typically worsen during withdrawal of the drug. Criteria for the diagnosis of tardive dyskinesia vary widely, and some observers include minor movements which are difficult to distinguish from habit spasms, mannerisms, or the spontaneous chewing movements seen in many of the normal elderly. Among the conditions that must be considered in the differential diagnosis are the stereotyped movements of schizophrenia, focal dystonias, Huntington's disease, Wilson's disease, and rheumatic chorea. Tardive dyskinesia may be assessed by using the abnormal involuntary movement scale (AIMS)3 or the more detailed Simpson scale.4
Despite the clear association between the use of antipsychotic drugs and the eventual development of tardive dyskinesia, the task force concluded that neither prolonged exposure nor exposure to large total amounts of drug was the determining factor: only a weak correlation may be shown between the daily dose and the occurrence oftardive dyskinesia.5 Older people and women may be more at risk, but among the factors that are not clinical predictors are the type of drug, dose, earlier acute reversible extrapyramidal symptoms, and treatment for Parkinson's disease. Nevertheless, between 10% and 20% of patients given antipsychotic drugs for a year or more develop clinically appreciable tardive dyskinesia, though disabling degrees of the condition are fortunately rare. Most patients improve substantially when medication is stopped, usually within months but sometimes after one to two years.
The aetiology of tardive dyskinesia was cautiously discussed by the task force. Antipsychotic drugs are dopamine-receptor antagonists and may induce secondary changes in dopamine systems consistent with supersensitivity.6 7 Much further research is needed, however, especially in primate models8 and human brain tissue obtained at necropsy.
For the individual patient who develops tardive dyskinesia the theoretical management consists in stopping treatment with antipsychotic drugs-but the psychosis may then become exacerbated. In consultation with the patient and family, the clinician must balance the risks of continuing treatment against those of halting it. The task force emphasised that "tardive dyskinesia seems not to be a uniformly and relentlessly progressive neurologic disorder," so that continuing treatment, at least in the short term, is usually justifiable if the patient's psychosis is active. Many remedies have been tried in tardive dyskinesia; none is effective. Increasing the dosage of the antipsychotic drugs only postpones the risk since further and perhaps more severe dyskinesia may develop later; amine-depleting drugs such as reserpine seem only temporarily effective; the results with acetylcholine-increasing drugs such as choline, lecithin, and deanol are unimpressive; while the benzodiazepines and other drugs acting on gamma-aminobutyric acid mechanisms provide only partial relief. Some of these apparently unpredictable responses may be due to tardive dyskinesias being a heterogeneous group of disorders with a variety of mechanisms.
In practical terms, then, clinicians should concentrate on ways of minimising the incidence of tardive dyskinesia. Antipsychotic drugs should be reserved for the short-term treatment of acute psychosis, including first attacks or exacerbation of schizophrenia, paranoid states, mania, some cases of toxic or organic psychosis, childhood psychoses, and as adjunctive treatment in psychotic depression. Their prolonged use (for over six months) is indicated only in the maintenance treatment of chronic psychotic disorders, mainly schizophrenia, in which a continuing response can be shown. Controlled studies have indicated that nearly half of all patients with chronic schizophrenia do not deteriorate while taking placebo.9 Antipsychotic medication should be evaluated at least once a year by reducing the dosage about 100% every three to seven days until the drug has been stopped completely or the clinical condition worsens. Not only will this procedure indicate whether antipsychotic medication is still beneficial: it will also help in detecting early withdrawal dyskinesia.
Finally, the problem of tardive dyskinesia has had two other spin-offs. It has led to psychiatrists trying to identify patients who do not need antipsychotic medication, and to pharmaceutical companies trying to develop more selective antipsychotic drugs devoid of extrapyramidal effects.
